Duvelisib

CHEMBL3039502 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
416.9 g/mol
LogP
4.1
Phase
4

A dual PI3K delta and gamma inhibitor used to treat chronic lymphocytic leukemia and follicular lymphoma in patients who have received prior therapy. It blocks signaling pathways that allow cancer cells to survive and proliferate.

分子量

416.9000 g/mol

LogP

4.10

TPSA

86.80 Ų

Lipinski 五规则

符合

治疗领域

Pharmacokinetics (PK)

Pharmacodynamics (PD)

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1

InChI

InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1

Molecular Formula

C22H17ClN6O

HBD / HBA

2 / 5

可旋转键数

4

重原子数

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A dual PI3K delta and gamma inhibitor used to treat chronic lymphocytic leukemia and follicular lymphoma in patients who have received prior therapy. It blocks signaling pathways that allow cancer cells to survive and proliferate.

Yes, Duvelisib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3039502. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 50905713. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.